ADVERTISEMENT |
2009 could be busy year for pharmacy issues in state legislatures
![]() "This is an opportunity to educate legislators on what's already in place," Trujillo said. "It's an opportunity to show them what is working, what isn't." Trujillo described 2008 as an active year for pharmacy issues. In Michigan, a medicinal medical marijuana law was approved and Washington State voters passed a Death with Dignity Law. A total of 49 states now allow pharmacists to immunize; several state legislatures are considering generic substitution proposals; and the movement to regulate, certify, and mandate specific training levels for pharmacy technicians is growing. This week, for example, representatives from 12 states joined ASHP's Pharmacy Technician Initiative effort to promote state laws regarding the training, registration, and certification of technicians. At the federal level, the Environmental Protection Agency is considering pharmaceutical waste disposal proposals. Among the pharmacy initiatives that several states are likely to consider in 2009 are technology issues such as online license renewals, which ASHP believes will benefit both pharmacy and state governments; remote prescription dispensing; and mutual recognition of licensure. Trujillo said state boards of pharmacies are definitely more focused on lobbying efforts, as healthcare reform seems to be on the national radar. But she cautioned pharmacists not to rely solely on lobbyists, but to voice their concerns to legislators. Brian M. Meyer, ASHP's director of government affairs division, echoed Trujillo's sentiments. "All politics is local, and it starts at the state legislative level," he said, adding that the "next Barack Obama" will be seated in a state legislature in January. Disclaimer This information has been independently developed and provided by the editors of Modern Medicine Primary Care Content Group. The sponsor does not endorse and is not responsible for the accuracy of the content, or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences please see the appropriate manufacturer's product circular. | ARCHIVES | RSS | E-NEWS | DIGITAL EDITION
![]()
Keep visiting Drug Topics for fresh content, news, opinions, editor's blogs and more. ![]()
|